GlassScriptPhysician profile
Navdeep Sood
NPI 1043231830
$51,437.83
in general payments reported to CMS, 2019-2025
20 companies · $25K in 2025
The $25K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $563 · 2021: $658 · 2022: $667 · 2023: $10K · 2024: $13K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Honoraria: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,500 · Food and Beverage: $3,496 · Travel and Lodging: $2,405 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,000 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,625.00 |
| Honoraria | $13,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,500.00 |
| Food and Beverage | $3,495.96 |
| Travel and Lodging | $2,404.81 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,000.00 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $38,118.08 | 2023-2025 | Auvelity |
| Abbvie INC. | $10,681.54 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $766.52 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Allergan, INC. | $464.40 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $384.59 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $243.16 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $193.64 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $100.72 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.70 | 2021-2022 | |
| Indivior INC. | $71.23 | 2022-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $67.69 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $61.22 | 2019-2023 | Invega Sustenna |
| Lundbeck LLC | $48.40 | 2019-2021 | |
| Brainsway USA INC | $36.33 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.28 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $24.19 | 2020 | |
| Eisai INC. | $20.02 | 2020 | |
| Merck Sharp & Dohme LLC | $13.80 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.73 | 2022 | |
| Neuronetics, INC. | $10.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navdeep Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.